Insights

While there is no “wrong” pathway to become a clinical research associate (CRA), the responses to a recent survey of current and former CRAs suggest an ideal pathway one might follow to optimize the ability for the potential candidate to receive as much experience as possible.

This article delves into the role of multi-omics in enhancing cancer clinical trials, highlighting its promise against the backdrop of frequent trial failures encountered in oncology research and limited success of precision medicine.

Diversity in clinical research has become a hot topic in recent years, with heightened attention leading to dramatic changes in the regulatory framework. The U.S. Food and Drug Administration Omnibus Reform Act of 2022 (FDORA) is one of the most notable. Now, just over a year since FDORA’s implementation, the industry’s perspective on diversity has undoubtedly evolved.

It can be difficult to find qualified and motivated candidates for clinical research job openings who are following all the rules. So, when competition gets so cutthroat that an entire shadow network of fake references springs up to help foist illegitimate new hires on short-staffed or over-eager employers via trickery, caution should be the hiring manager’s byword.

Recently, an industry driven by metrics admitted it’s probably not making the most of its data. This conclusion—noted in the marketing sector—offers both a warning and sound advice for the pharmaceutical industry, which collects data from its investigator meetings, speaker trainings, and ad boards, but often doesn’t have all necessary resources to convert this information into meaningful metrics and actionable insights that can impact business strategy.